The comparison between the Agilus injection and the saline control injection groups in the proportion of subjects experiencing a reduction in the assessment of pain determined by the AOS subscale for pain. At 4, 12 and 26 weeks post 3rd injection [clinicaltrials_resource:24dafef4611e8cc104756a88488c2400]
Agilus (Hyaluronic Acid)
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
The comparison between the Agilus injection and the saline control injection groups in the proportion of subjects experiencing a reduction in the assessment of pain determined by the AOS subscale for pain. At 4, 12 and 26 weeks post 3rd injection [clinicaltrials_resource:24dafef4611e8cc104756a88488c2400]
Agilus (Hyaluronic Acid)
Bio2RDF identifier
24dafef4611e8cc104756a88488c2400
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:24dafef4611e8cc104756a88488c2400
measure [clinicaltrials_vocabulary:measure]
The comparison between the Agi ...... by the AOS subscale for pain.
time frame [clinicaltrials_vocabulary:time-frame]
At 4, 12 and 26 weeks post 3rd injection
description
Agilus (Hyaluronic Acid)
identifier
clinicaltrials_resource:24dafef4611e8cc104756a88488c2400
title
The comparison between the Agi ...... nd 26 weeks post 3rd injection
@en
type
label
The comparison between the Agi ...... afef4611e8cc104756a88488c2400]
@en